MERZ
PharmaMERZ is a pharmaceutical company focused on Neurology, Dermatology, Ophthalmology. Key products include INBRIJA.
MERZ at a Glance
- Strong track record with 90% execution quality across 15 trials
- Fast trial execution (15 months median completion)
MERZ's Key Drugs
MERZ's core commercial portfolio centers on INBRIJA, spanning Neurology and Dermatology — its most strategically important drugs approved in the last 15 years.
MERZ's Recent FDA Approvals
New NDA/BLA approvals for MERZ over the last two years — novel drugs only, excluding generics and label supplements.
MERZ's Therapeutic Areas
MERZ's approved drugs and pipeline span 3 therapeutic areas, led by Neurology and Dermatology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MERZ's Top Competitors
MERZ's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and OTSUKA. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MERZ Pipeline Snapshot
MERZ has 9 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 2 Phase 2 and 3 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • INBRIJA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 7/8 completed
- • Speed: 15 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2010-01-22
- Latest
- 2026-03-31
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges